HK Stock MarketDetailed Quotes

03320 CHINARES PHARMA

Watchlist

5.430
+0.020+0.37%

Not Open Dec 16 16:08 CST

34.11BMarket Cap8.24P/E (TTM)

CHINARES PHARMA Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(Q6)Jun 30, 2020

(FY)Dec 31, 2019

Turnover

4.71%128.6B

12.16%244.7B

-2.31%122.82B

-7.86%218.18B

9.81%125.72B

18.15%236.81B

28.08%114.49B

-1.97%200.42B

-12.30%89.39B

7.78%204.45B

Operating income

4.71%128.6B

12.16%244.7B

-2.31%122.82B

-7.86%218.18B

9.81%125.72B

18.15%236.81B

28.08%114.49B

-1.97%200.42B

-12.30%89.39B

7.78%204.45B

Cost of sales

-4.47%-107.66B

-11.81%-206.37B

2.67%-103.06B

8.37%-184.56B

-9.13%-105.88B

-19.80%-201.43B

-30.20%-97.02B

1.35%-168.13B

11.80%-74.52B

-10.13%-170.44B

Operating expenses

-4.47%-107.66B

-11.81%-206.37B

2.67%-103.06B

8.37%-184.56B

-9.13%-105.88B

-19.80%-201.43B

-30.20%-97.02B

1.35%-168.13B

11.80%-74.52B

-10.13%-170.44B

Gross profit

5.94%20.93B

14.04%38.34B

-0.36%19.76B

-4.98%33.62B

13.55%19.83B

9.56%35.38B

17.48%17.47B

-5.07%32.29B

-14.72%14.87B

-2.61%34.02B

Selling expenses

-1.49%-9.38B

-15.34%-18.91B

-1.80%-9.24B

6.48%-16.4B

-9.59%-9.08B

-9.37%-17.53B

-22.35%-8.28B

16.46%-16.03B

24.06%-6.77B

-4.62%-19.19B

Administrative expenses

-7.00%-3.04B

-13.44%-6.33B

2.98%-2.85B

10.55%-5.58B

-8.58%-2.93B

-12.07%-6.24B

-25.74%-2.7B

-6.93%-5.56B

8.28%-2.15B

-8.56%-5.2B

Operating interest expense

----

7.39%-1.36B

12.96%-2.74B

5.32%-1.47B

15.06%-3.15B

---1.55B

---3.71B

Special items of operating profit

-110.78%-857.54M

2.47%-1.84B

-542.26%-406.85M

-143.49%-1.88B

-540.76%-63.35M

-14.13%-773.81M

-28.30%14.37M

-215.67%-677.99M

-97.90%20.05M

15.80%586.15M

Operating profit

5.31%7.65B

15.37%11.26B

13.64%7.27B

20.58%9.76B

27.31%6.4B

17.85%8.09B

13.80%5.02B

5.69%6.87B

-38.10%4.41B

-47.17%6.5B

Financing income

59.52%372.15M

-18.51%587.69M

--233.3M

--721.18M

----

Financing cost

17.60%-1.18B

2.74%-2.39B

---1.43B

---2.45B

----

Share of profits of associates

-6.25%198.77M

25.51%417.11M

14.04%212.01M

5.98%332.34M

30.26%185.91M

51.60%313.6M

89.37%142.73M

47.31%206.85M

11.51%75.37M

2.37%140.42M

Earning before tax

12.14%7.05B

18.17%9.88B

-4.53%6.28B

-0.56%8.36B

27.39%6.58B

18.84%8.41B

15.07%5.17B

6.57%7.08B

-22.70%4.49B

-28.16%6.64B

Tax

-20.05%-1.51B

-23.61%-2.11B

11.23%-1.25B

3.29%-1.7B

-31.85%-1.41B

-0.52%-1.76B

-27.28%-1.07B

-13.63%-1.75B

25.16%-841.83M

4.25%-1.54B

After-tax profit from continuing operations

10.17%5.54B

16.78%7.78B

-2.69%5.03B

0.16%6.66B

26.23%5.17B

24.87%6.65B

12.25%4.09B

4.43%5.32B

-22.11%3.65B

-33.21%5.1B

Earning after tax

10.17%5.54B

16.78%7.78B

-2.69%5.03B

0.16%6.66B

26.23%5.17B

24.87%6.65B

12.25%4.09B

4.43%5.32B

-22.11%3.65B

-33.21%5.1B

Minority profit

25.06%2.94B

24.17%3.92B

9.53%2.35B

9.70%3.16B

29.40%2.14B

42.04%2.88B

54.71%1.66B

11.88%2.03B

-35.03%1.07B

-49.61%1.81B

Profit attributable to shareholders

-2.87%2.6B

10.11%3.85B

-11.35%2.68B

-7.13%3.5B

24.07%3.03B

14.31%3.77B

-5.40%2.44B

0.33%3.3B

-15.09%2.58B

-18.61%3.29B

Basic earnings per share

-4.65%0.41

8.93%0.61

-10.42%0.43

-6.67%0.56

23.08%0.48

15.38%0.6

-4.88%0.39

0.00%0.52

-14.58%0.41

-18.75%0.52

Diluted earnings per share

-4.65%0.41

8.93%0.61

-10.42%0.43

-6.67%0.56

23.08%0.48

15.38%0.6

-4.88%0.39

0.00%0.52

-14.58%0.41

-18.75%0.52

Currency Unit

CNY

HKD

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(Q6)Jun 30, 2020	(FY)Dec 31, 2019
Turnover	4.71%128.6B	12.16%244.7B	-2.31%122.82B	-7.86%218.18B	9.81%125.72B	18.15%236.81B	28.08%114.49B	-1.97%200.42B	-12.30%89.39B	7.78%204.45B
Operating income	4.71%128.6B	12.16%244.7B	-2.31%122.82B	-7.86%218.18B	9.81%125.72B	18.15%236.81B	28.08%114.49B	-1.97%200.42B	-12.30%89.39B	7.78%204.45B
Cost of sales	-4.47%-107.66B	-11.81%-206.37B	2.67%-103.06B	8.37%-184.56B	-9.13%-105.88B	-19.80%-201.43B	-30.20%-97.02B	1.35%-168.13B	11.80%-74.52B	-10.13%-170.44B
Operating expenses	-4.47%-107.66B	-11.81%-206.37B	2.67%-103.06B	8.37%-184.56B	-9.13%-105.88B	-19.80%-201.43B	-30.20%-97.02B	1.35%-168.13B	11.80%-74.52B	-10.13%-170.44B
Gross profit	5.94%20.93B	14.04%38.34B	-0.36%19.76B	-4.98%33.62B	13.55%19.83B	9.56%35.38B	17.48%17.47B	-5.07%32.29B	-14.72%14.87B	-2.61%34.02B
Selling expenses	-1.49%-9.38B	-15.34%-18.91B	-1.80%-9.24B	6.48%-16.4B	-9.59%-9.08B	-9.37%-17.53B	-22.35%-8.28B	16.46%-16.03B	24.06%-6.77B	-4.62%-19.19B
Administrative expenses	-7.00%-3.04B	-13.44%-6.33B	2.98%-2.85B	10.55%-5.58B	-8.58%-2.93B	-12.07%-6.24B	-25.74%-2.7B	-6.93%-5.56B	8.28%-2.15B	-8.56%-5.2B
Operating interest expense	----	----	----	----	7.39%-1.36B	12.96%-2.74B	5.32%-1.47B	15.06%-3.15B	---1.55B	---3.71B
Special items of operating profit	-110.78%-857.54M	2.47%-1.84B	-542.26%-406.85M	-143.49%-1.88B	-540.76%-63.35M	-14.13%-773.81M	-28.30%14.37M	-215.67%-677.99M	-97.90%20.05M	15.80%586.15M
Operating profit	5.31%7.65B	15.37%11.26B	13.64%7.27B	20.58%9.76B	27.31%6.4B	17.85%8.09B	13.80%5.02B	5.69%6.87B	-38.10%4.41B	-47.17%6.5B
Financing income	59.52%372.15M	-18.51%587.69M	--233.3M	--721.18M	----	----	----	----	----	----
Financing cost	17.60%-1.18B	2.74%-2.39B	---1.43B	---2.45B	----	----	----	----	----	----
Share of profits of associates	-6.25%198.77M	25.51%417.11M	14.04%212.01M	5.98%332.34M	30.26%185.91M	51.60%313.6M	89.37%142.73M	47.31%206.85M	11.51%75.37M	2.37%140.42M
Earning before tax	12.14%7.05B	18.17%9.88B	-4.53%6.28B	-0.56%8.36B	27.39%6.58B	18.84%8.41B	15.07%5.17B	6.57%7.08B	-22.70%4.49B	-28.16%6.64B
Tax	-20.05%-1.51B	-23.61%-2.11B	11.23%-1.25B	3.29%-1.7B	-31.85%-1.41B	-0.52%-1.76B	-27.28%-1.07B	-13.63%-1.75B	25.16%-841.83M	4.25%-1.54B
After-tax profit from continuing operations	10.17%5.54B	16.78%7.78B	-2.69%5.03B	0.16%6.66B	26.23%5.17B	24.87%6.65B	12.25%4.09B	4.43%5.32B	-22.11%3.65B	-33.21%5.1B
Earning after tax	10.17%5.54B	16.78%7.78B	-2.69%5.03B	0.16%6.66B	26.23%5.17B	24.87%6.65B	12.25%4.09B	4.43%5.32B	-22.11%3.65B	-33.21%5.1B
Minority profit	25.06%2.94B	24.17%3.92B	9.53%2.35B	9.70%3.16B	29.40%2.14B	42.04%2.88B	54.71%1.66B	11.88%2.03B	-35.03%1.07B	-49.61%1.81B
Profit attributable to shareholders	-2.87%2.6B	10.11%3.85B	-11.35%2.68B	-7.13%3.5B	24.07%3.03B	14.31%3.77B	-5.40%2.44B	0.33%3.3B	-15.09%2.58B	-18.61%3.29B
Basic earnings per share	-4.65%0.41	8.93%0.61	-10.42%0.43	-6.67%0.56	23.08%0.48	15.38%0.6	-4.88%0.39	0.00%0.52	-14.58%0.41	-18.75%0.52
Diluted earnings per share	-4.65%0.41	8.93%0.61	-10.42%0.43	-6.67%0.56	23.08%0.48	15.38%0.6	-4.88%0.39	0.00%0.52	-14.58%0.41	-18.75%0.52
Currency Unit	CNY	CNY	CNY	CNY	HKD	HKD	HKD	HKD	HKD	HKD
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion
Auditor	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

Investment Theme

Chinese SOEs

Intraday+0.33%

Traditional Chinese Medicine

Intraday-1.53%

03320 CHINARES PHARMA

CHINARES PHARMA Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow